ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1133

Factors for Opioids Use in the Early Treatment Options for the Knee Osteoarthritis Patients

Soo-Kyung Cho1, Seongmi Choi2, Seul Gi Im2, Hyoungyoung Kim1, Sun-Young Jung3, Eun Jin Jang4 and Yoon-Kyoung Sung5, 1Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), 2Statistics, Kyungpook National University, Daegu, Korea, Republic of (South), 3College of Pharmacy, Chung-Ang University, Seoul, Korea, Republic of (South), 4Information Statistics, Andong National University, Andong-si, Korea, Republic of (South), 5Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Elderly, Knee, medical management, Opioids and osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Current guidelines for osteoarthritis (OA) treatment recommend a range of nonpharmacological and pharmacological interventions to alleviate pain, improve function and quality of life. Most guidelines do not recommend opioids for OA treatment as an early treatment option, but some guidelines suggest using opioids on a restricted basis for short-term use in select patients with refractory symptoms. Although opioids can emerge as a treatment option that may provide effective pain relief with less risk than NSAIDs, they have the potential to cause harm. Until now, the current burden of opioid use for knee OA in Korea is not well understood. We investigated how many prescriptions of opioids for early knee OA treatment are given in Korea, and examined the factors related with opioid use in the early treatment options for knee OA.

Methods: Using the Korean nationwide claims database, all knee OA patients during 2013-2015 were identified by our validated operational definition. Among them, we extracted incident cases to identify opioid use in the early treatment options for knee OA patients. Opioids included tramadol as a weak opioid, and the utilization of opioids was analyzed by dividing strong opioids and weak opioids. A multivariable model was constructed to examine the factors related with opioids use.

Results: Among a total of 2,857,999 incident knee OA patients, 12.2% (n=348,516) were treated with opioids in their first year after diagnosis. However, strong opioid use (not including tramadol) was only 0.07% among the knee OA patients (n=1,972). Opioid users were slightly older (64.2 vs. 64.0 years old, p<0.01) and more likely to be male (44.0% vs. 37.8%, p<0.01) than opioid non users. Most of the opioids (88.6%) were prescribed in community hospitals and clinics. The frequency of opioid prescription was highest in the department of orthopedic surgery (70.1%), followed by internists (9.7%). Elixhauser comorbidity index score was higher in opioid users (4.51±6.36 vs. 4.43±6.23, p<0.01). Related factors with early opioid use were older age (≥70 years old: odds ratio [OR], 1.02; 95% confidence interval [CI], 1.01-1.03, reference 50-59 years old), male (OR 1.29; 95% CI, 1.28-1.30), and medical aid patients (OR 1.13; 95% CI, 1.12-1.15). In terms of comorbidities present, there were peptic ulcer disease (PUD) (OR 1.03; 95% CI, 1.02-1.04), depression (OR 1.05, 95% CI, 1.04-1.06), and musculoskeletal diseases (low back pain: OR 1.12; 95% CI, 1.12-1.13, intervertebral disc: OR 1.11, 95% CI, 1.10-1.13, spinal stenosis: OR 1.27, 95% CI, 1.26-1.29, fibromyalgia: OR 1.14, 95% CI, 1.11-1.17), while diabetes (OR 0.98, 95% CI, 0.97-0.99) and malignancy (OR 0.89, 95% CI, 0.88-0.90) were protective.

Conclusion: In Korea, strong opioid use is not common as a treatment option for early knee OA treatment, but tramadol use is common. Being elderly, male, having comorbidities such as PUD and musculoskeletal diseases, and medical aid patients were more likely to be treated with strong opioids or tramadol.


Disclosure: S. K. Cho, None; S. Choi, None; S. G. Im, None; H. Kim, None; S. Y. Jung, None; E. J. Jang, None; Y. K. Sung, None.

To cite this abstract in AMA style:

Cho SK, Choi S, Im SG, Kim H, Jung SY, Jang EJ, Sung YK. Factors for Opioids Use in the Early Treatment Options for the Knee Osteoarthritis Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/factors-for-opioids-use-in-the-early-treatment-options-for-the-knee-osteoarthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-for-opioids-use-in-the-early-treatment-options-for-the-knee-osteoarthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology